|4Oct 6, 8:16 AM ET

Gangolli Julian S 4

4 · Outlook Therapeutics, Inc. · Filed Oct 6, 2023

Insider Transaction Report

Form 4
Period: 2023-10-04
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-10-04+370,282370,282 total
    Exercise: $0.24Exp: 2033-10-04Common Stock (370,282 underlying)
Footnotes (1)
  • [F1]The options were granted under the 2015 Plan in lieu of $77,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION